Liver Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Primary liver cancer arises from hepatic cells and encompasses several histological subtypes. Hepatocellular carcinoma (HCC) accounts for 75-85% of cases and typically develops on a background of chronic liver disease — hepatitis B or C infection, alcohol-related cirrhosis, or metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Intrahepatic cholangiocarcinoma (iCCA) arises from the bile duct epithelium within the liver and accounts for approximately 10-15% of primary liver cancers; its incidence is rising globally. Secondary liver metastases from colorectal, breast, pancreatic, or lung cancers are far more common than primary liver cancers but require different management algorithms.

Treatment selection for HCC is guided by the Barcelona Clinic Liver Cancer (BCLC) staging and treatment allocation algorithm, endorsed by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). The BCLC system integrates tumour characteristics (number, size, vascular invasion, extrahepatic spread), liver functional reserve (Child-Pugh score, bilirubin, portal hypertension), and performance status (ECOG PS) to allocate patients to treatment categories with evidence-based survival outcomes.

The global incidence of HCC exceeds 900,000 new cases annually, with the highest burden in sub-Saharan Africa and East Asia. In endemic areas, hepatitis B surface antigen (HBsAg) carriers and patients with cirrhosis of any aetiology should undergo HCC surveillance with liver ultrasound and serum alpha-fetoprotein (AFP) every 6 months, as surveillance has been shown to detect tumours at an earlier, potentially curative stage and improve overall survival.

The BCLC staging system classifies HCC into five stages with corresponding first-line treatments:

BCLC Stage 0 (Very Early): A single tumour less than 2 cm in a Child-Pugh A patient with ECOG PS 0. First-line: resection or ablation (radiofrequency ablation, RFA). Five-year survival exceeds 70% with resection.

BCLC Stage A (Early): Single tumour of any size, or up to 3 nodules each under 3 cm, in a Child-Pugh A/B patient with ECOG PS 0. First-line: resection (for single nodules with adequate hepatic reserve), ablation (for tumours under 3 cm or when resection is not feasible), or liver transplantation within Milan criteria. Five-year survival is 50-75% with transplantation.

BCLC Stage B (Intermediate): Multinodular HCC without vascular invasion or extrahepatic spread, in a Child-Pugh A/B patient with ECOG PS 0. First-line: transarterial chemoembolisation (TACE). Median survival is 26-30 months with TACE.

BCLC Stage C (Advanced): HCC with macrovascular invasion (portal vein tumour thrombus), extrahepatic metastases, or ECOG PS 1-2 in a Child-Pugh A/B patient. First-line: atezolizumab + bevacizumab (IMbrave150 trial) or lenvatinib; second-line: sorafenib, cabozantinib, or regorafenib. Median overall survival with first-line immunotherapy-targeted combination is 19-20 months.

BCLC Stage D (End-Stage): End-stage liver disease (Child-Pugh C) or ECOG PS 3-4. First-line: best supportive care. Median survival is under 3 months regardless of treatment.

Intrahepatic cholangiocarcinoma (iCCA) is staged using the American Joint Committee on Cancer (AJCC) TNM system. Surgical resection with R0 margins is the only curative option for localised iCCA. For advanced or unresectable iCCA, the TOPAZ-1 trial established durvalumab plus gemcitabine/cisplatin as the new standard of care, improving overall survival from 11.5 months (gemcitabine/cisplatin alone) to 12.9 months and demonstrating a significant 24-month survival benefit (24.9% vs 10.4%).

Liver transplantation eligibility for HCC is defined by the Milan criteria: a single tumour no greater than 5 cm in diameter, or up to three tumours each no greater than 3 cm, with no macrovascular invasion or extrahepatic disease. Within these criteria, post-transplant 5-year survival exceeds 70% with HCC recurrence rates under 15%. Extended criteria such as the University of California San Francisco (UCSF) criteria (single tumour up to 6.5 cm or up to 3 tumours with the largest no greater than 4.5 cm and total tumour diameter no more than 8 cm) have been adopted by some centres.

Patients initially outside Milan criteria may be downstaged to within Milan criteria using locoregional therapy (TACE or ablation) and subsequently listed for transplantation if tumour response is achieved and sustained for a minimum of 3-6 months. Downstaging programmes have achieved successful transplantation in 25-30% of patients originally outside criteria.

Surgical resection is considered for BCLC 0/A patients with adequate functional hepatic reserve, defined as future liver remnant (FLR) volume above 20-25% in normal liver or 40% in cirrhotic liver. Portal vein embolisation (PVE) can be performed pre-operatively to induce contralateral hepatic hypertrophy and increase FLR volume when resection is otherwise limited by reserve.

RFA eligibility: Single tumours less than 3 cm achieve comparable outcomes to resection in multiple randomised trials and are generally preferred for BCLC 0 tumours in high-risk surgical candidates. For tumours 3-5 cm, microwave ablation (MWA) produces larger ablation zones than RFA with comparable local control rates and may be preferred. TACE is generally contraindicated in Child-Pugh C, main portal vein thrombosis, hepatic encephalopathy, jaundice with bilirubin above 3 mg/dL, and platelet count below 50,000/microlitre.

Surgical Resection: Hepatic resection for HCC involves anatomical removal of the tumour-bearing segment(s) with adequate parenchymal margins. Laparoscopic hepatectomy has comparable oncological outcomes to open resection for peripheral and anterolateral lesions and offers reduced blood loss, shorter hospital stay (3-5 vs 7-10 days), and faster recovery. Robotic hepatectomy is increasingly available in specialised centres. Five-year survival after resection ranges from 40-70% depending on tumour stage, vascular invasion, and liver function.

Radiofrequency Ablation (RFA) and Microwave Ablation (MWA): RFA uses alternating electrical current at 375-500 kHz to produce frictional heating and coagulative necrosis within a 3-5 cm zone. MWA generates oscillating electromagnetic fields at 900-2,450 MHz, producing larger ablation zones (4-6 cm) with shorter treatment times and less susceptibility to heat-sink effects near large vessels. Both can be performed percutaneously (under CT or ultrasound guidance), laparoscopically, or intraoperatively. For BCLC 0-A tumours under 3 cm, RFA achieves complete response in 90-97% of cases.

Transarterial Chemoembolisation (TACE): TACE exploits the predominantly arterial blood supply of HCC to deliver concentrated chemotherapy (doxorubicin, cisplatin, or mitomycin C) emulsified with iodised oil (Lipiodol) directly to the tumour, followed by embolisation of the feeding artery to induce ischaemic necrosis. Drug-eluting bead TACE (DEB-TACE) loads drug-eluting microspheres (DC Bead) with doxorubicin, providing sustained local drug release with reduced systemic exposure. Meta-analyses show equivalent tumour response between conventional TACE and DEB-TACE, with lower systemic toxicity for DEB-TACE. Median survival with TACE for intermediate-stage HCC is 26-30 months.

Y-90 Selective Internal Radiation Therapy (SIRT): SIRT delivers yttrium-90 microspheres (SIR-Spheres or TheraSphere) via the hepatic artery to deliver tumoricidal doses of radiation (100-150 Gy to tumour) while sparing normal liver. In HCC, the SARAH trial (France) and SIRveNIB trial (Asia-Pacific) compared Y-90 SIRT with sorafenib in advanced HCC and found comparable overall survival with a superior tolerability profile for SIRT. SIRT is increasingly used as a bridging therapy to transplantation and for downstaging.

Systemic Therapy for Advanced HCC: The IMbrave150 trial (NEJM 2020) compared atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) versus sorafenib in previously untreated advanced HCC. Atezolizumab-bevacizumab significantly improved overall survival (median 19.2 vs 13.4 months), progression-free survival, and objective response rate (30% vs 11%) and replaced sorafenib as the preferred first-line regimen for Child-Pugh A advanced HCC. Lenvatinib (a multi-kinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGFR-alpha, RET, and KIT) demonstrated non-inferiority to sorafenib in the REFLECT trial (overall survival 13.6 vs 12.3 months) with a higher objective response rate (24% vs 9%) and is a first-line alternative. Second-line agents after sorafenib failure include regorafenib (RESORCE trial), cabozantinib (CELESTIAL trial), and ramucirumab (REACH-2 trial, for AFP above 400 ng/mL).

The primary goal of HCC treatment is cure for early-stage disease and meaningful survival prolongation with preservation of quality of life for intermediate and advanced stages. Long-term survival outcomes differ markedly by stage and treatment.

Liver transplantation within Milan criteria achieves the best long-term outcomes for HCC with underlying cirrhosis, offering simultaneous cure of the tumour and the underlying liver disease (cirrhosis). Five-year post-transplant survival exceeds 70-75% in well-selected patients, compared with 40-70% for resection and 50-70% for ablation at BCLC 0/A, with transplantation providing the lowest tumour recurrence rate (under 15%).

For BCLC B patients, TACE provides meaningful life extension compared with best supportive care. Two landmark randomised controlled trials (Llovet 2002; Lo 2002) established the survival benefit of TACE over supportive care, with 2-year survival improving from 27% (supportive care) to 63% (TACE) in the Spanish trial.

The IMbrave150 immunotherapy combination represents the largest improvement in advanced HCC survival in over a decade. One-year survival rates of 67.2% versus 54.6% (sorafenib), with over 30% of patients achieving objective tumour responses, has transformed the outlook for BCLC C disease. Durable complete responses — rare with sorafenib — occur in approximately 6% of patients receiving atezolizumab-bevacizumab.

For iCCA, the TOPAZ-1 trial results represent the first improvement in first-line systemic therapy in over a decade, with durvalumab added to chemotherapy extending median overall survival by 1.4 months (12.9 vs 11.5 months) and improving 24-month survival rates (24.9% vs 10.4%).

Surgical resection carries risks proportional to the extent of hepatectomy and underlying liver function. Post-hepatectomy liver failure (PHLF) is the most feared complication, particularly in cirrhotic patients. The 50-50 criteria (bilirubin above 50 micromol/L and prothrombin ratio below 50% on post-operative day 5) identify patients at high risk of PHLF. Bile leakage, post-operative haemorrhage, and wound infection are additional surgical risks. Operative mortality in specialised hepatobiliary centres is 1-3% for major hepatectomy.

RFA and MWA complications include a post-ablation syndrome (fever, malaise, pain) occurring in 30-50% of patients for 1-7 days after treatment. Serious complications including haemorrhage, bile duct injury (biloma), skin burns, tumour seeding along the needle tract (rare, 0.5-1%), and pneumothorax occur in 2-5% of percutaneous ablations.

Post-TACE syndrome — fever, right upper quadrant pain, nausea, and elevated liver enzymes — occurs in up to 80% of patients and is expected as a sign of therapeutic necrosis. Serious TACE complications include hepatic abscess (1-4%), hepatic artery injury, non-target embolisation to bowel or gallbladder, and acute liver decompensation (2-5%), which is most common in Child-Pugh B patients with poor hepatic reserve.

Atezolizumab-bevacizumab adverse effects include immune-mediated toxicities (hepatitis, colitis, pneumonitis, endocrinopathies) from the PD-L1 inhibitor and bevacizumab-related effects (hypertension in 30%, haemorrhage, thromboembolism, proteinuria, wound healing impairment). Atezolizumab-bevacizumab is contraindicated in patients with untreated or inadequately controlled varices (bleeding risk) and autoimmune conditions requiring systemic immunosuppression. Variceal screening by upper GI endoscopy is mandatory before starting atezolizumab-bevacizumab.

Lenvatinib commonly causes hypertension (40-45%), fatigue (44%), diarrhoea (39%), decreased appetite (34%), and palmar-plantar erythrodysaesthesia (27%). Sorafenib toxicities include hand-foot skin reaction (21%), diarrhoea (55%), fatigue, and hypertension.

Post-treatment surveillance aims to detect HCC recurrence or de novo tumours, which occur in 50-70% of patients within 5 years after resection or ablation due to the ongoing risk from underlying cirrhosis.

After resection or ablation, contrast-enhanced CT or MRI of the liver is recommended every 3-4 months for the first 2 years and every 6 months thereafter. Liver MRI with gadoxetic acid (Primovist/Eovist) provides superior tumour detection compared with CT and is preferred at experienced centres. AFP monitoring every 3 months accompanies imaging in AFP-secreting tumours.

For patients on systemic therapy (atezolizumab-bevacizumab, lenvatinib, or sorafenib), response assessment using modified RECIST (mRECIST) criteria — which measures viable enhancing tumour rather than total tumour diameter — is performed at 6-8 weeks and every 8-12 weeks thereafter. Complete radiological response, partial response, stable disease, and progressive disease guide continuation, dose modification, or switching of systemic therapy.

Liver transplant recipients require lifelong post-transplant monitoring: tacrolimus or cyclosporin-based immunosuppression trough level monitoring, renal function, blood pressure, glucose, and lipids for metabolic complications; HCC surveillance with AFP and CT/MRI every 6 months for 5 years (highest recurrence risk is in the first 2 years); and monitoring for immunosuppression-related complications including opportunistic infections, de novo malignancy, and nephrotoxicity.

Patients with hepatitis B-related HCC must receive antiviral therapy (tenofovir alafenamide or entecavir) indefinitely to suppress viral replication, reduce risk of disease progression in the remnant liver, and prevent HBV reactivation during systemic anti-cancer therapy.

Liver cancer treatment costs are substantial and vary markedly by modality, country, and healthcare system. In the United States, liver resection for HCC costs USD 50,000-120,000 including hospital stay; liver transplantation costs USD 300,000-500,000 for the procedure plus ongoing immunosuppression costs of USD 10,000-20,000 per year. Atezolizumab-bevacizumab (Tecentriq + Avastin) costs approximately USD 15,000-20,000 per month in the US before insurance or patient assistance programme discounts. Sorafenib (Nexavar) and lenvatinib (Lenvima) cost approximately USD 11,000-13,000 per month at list price.

In Europe, HCC treatments are generally covered by national health systems under established oncology pathways. Patient access programmes and national negotiated pricing reduce immunotherapy costs substantially.

For medical tourism, India, Thailand, and Singapore offer specialised hepatobiliary oncology at internationally accredited centres at significantly lower cost. Liver resection for HCC in India ranges from INR 250,000-600,000 (approximately USD 3,000-7,200). TACE in India ranges from INR 80,000-200,000 (USD 960-2,400) per session. Liver transplantation in India costs USD 25,000-50,000 total, representing significant savings compared with Western countries while maintaining NABH or JCI accreditation.

Cost-effectiveness analyses favour liver transplantation for eligible patients over long-term TACE or systemic therapy due to superior long-term survival. For advanced HCC, immunotherapy combinations are cost-effective relative to sorafenib when accounting for improved survival and quality-adjusted life years (QALYs) in most health economic models.

The liver cancer treatment landscape is rapidly evolving, with multiple new agents and combinations entering clinical practice or undergoing investigation.

Combination immunotherapy regimens are expanding first-line options for advanced HCC. The HIMALAYA trial demonstrated that durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) in the STRIDE regimen improved overall survival versus sorafenib (median OS 16.4 vs 13.8 months), with a 4-year OS rate of 25.2%, representing durable long-term survival benefit from dual checkpoint blockade. Nivolumab plus ipilimumab (CheckMate 040) showed meaningful durable responses (32% ORR; 17-month median duration of response) in the second-line setting.

Stereotactic body radiation therapy (SBRT) delivers high-dose radiation (30-60 Gy in 3-5 fractions) with millimetre precision to HCC, sparing adjacent liver parenchyma. SBRT has achieved local control rates of 70-90% for tumours under 6 cm and is increasingly used as an alternative to TACE for BCLC B patients with portal vein tumour thrombus and as a bridge to transplantation.

Hepatic artery infusion chemotherapy (HAIC) with FOLFOX (oxaliplatin, fluorouracil, leucovorin) is used predominantly in Asia for advanced HCC with portal vein tumour thrombus. The FOHAIC-1 trial demonstrated superior outcomes versus sorafenib in this population (overall survival 13.4 vs 7.1 months).

For intrahepatic cholangiocarcinoma, IDH1 mutation (present in 15-20% of iCCA) is targetable with ivosidenib (ClarIDHy trial: improved progression-free survival vs placebo). FGFR2 fusions or rearrangements (present in 10-16% of iCCA) are treated with pemigatinib or infigratinib, both approved for second-line use. The TOPAZ-1 regimen (durvalumab + gemcitabine/cisplatin) is now the first-line standard for advanced biliary tract cancers.

Liver-directed radioembolisation with Y-90 glass microspheres (TheraSphere) in radiation segmentectomy or radiation lobectomy technique applies ablative doses to a single segment or lobe, achieving complete tumour response rates of 55-65% for early-stage HCC not amenable to surgical or ablative treatment.